Citius Oncology, Inc. (CTOR)
Nasdaq: CTOR · Pharmaceutical Preparations · Cranford, NJ · filing with the SEC since 2021
Income statement, as filed
In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in September.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period ending | Sep 30, 2025 | Sep 30, 2024 | Dec 31, 2023 | Sep 30, 2023 | Dec 31, 2022 |
| Report filed | Dec 23, 2025 | Dec 27, 2024 | Apr 16, 2024 | · | Apr 17, 2023 |
| Research and development | 6,418,334 | 4,925,001 | · | 4,240,451 | · |
| General and administrative | 8,783,997 | 8,148,929 | 1,013,070 | 5,915,290 | 138,115 |
| Total operating expenses | 23,522,750 | 20,572,747 | · | 12,121,241 | · |
| Operating income | -23,522,750 | -20,572,747 | -1,013,070 | · | -138,115 |
| Interest expense | 218,032 | · | · | · | · |
| Interest and investment income | 36,373 | · | · | · | · |
| Total non-operating income (expense) | -181,659 | · | 3,432,374 | · | 518,926 |
| Income before income taxes | -23,704,409 | -20,572,747 | · | -12,121,241 | · |
| Income tax expense | 1,056,960 | 576,000 | · | 576,000 | · |
| Net income | -24,761,369 | -21,148,747 | 2,419,304 | -12,697,241 | 380,811 |
| Earnings per share, basic | -0.34 | -0.31 | 0.27 | -0.19 | 0.12 |
| Earnings per share, diluted | -0.34 | -0.31 | 0.27 | -0.19 | 0.12 |
| Weighted average shares, basic | 73,267,969 | 68,053,607 | 6,600,000 | 67,500,000 | 1,341,758r |
| Weighted average shares, diluted | 73,267,969 | 68,053,607 | 6,600,000 | 67,500,000 | 1,341,758 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Research and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding